[시장보고서]경구 고형 제제 CDMO 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 메커니즘별, 약효별, 서비스별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

경구 고형 제제 CDMO 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 메커니즘별, 약효별, 서비스별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Oral Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Product (Tablets, Capsules, Powder, Granules), By Mechanism, By Drug Potency, By Service, By End Use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1908693

리서치사 : Grand View Research

발행일 : 2025년 12월

페이지 정보 : 영문 250 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,782,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,258,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,211,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

경구 고형 제제 CDMO 시장 요약

세계의 경구 고형 제제 CDMO 시장 규모는 2024년에 436억 5,000만 달러로 추정되며, 2033년까지 770억 6,000만 달러에 이를 것으로 예측됩니다.

또한, 2025-2033년까지 연평균 6.56% 성장할 것으로 예측됩니다. 시장 성장의 주요 요인으로는 비용 효율적인 의약품 개발에 대한 수요 증가, 제약 및 생명공학 기업의 아웃소싱 확대, 만성질환 및 생활습관병 치료용 정제 및 캡슐제 소비 확대 등을 꼽을 수 있습니다. 이는 투여의 용이성과 정확한 용량 관리가 가능하기 때문에 경구용 고형제제제 CDMO 서비스에 대한 수요가 증가하고 있습니다.

기타 시장 성장 촉진요인으로는 제네릭 의약품의 확대, 특허 만료, 유연한 제조 능력의 필요성 등을 들 수 있습니다. 많은 기업들이 CDMO에 의존하여 첨단 제형 기술에 대한 접근, 효율적인 생산 확대, 엄격한 규제 및 품질 요구 사항에 대한 대응을 위해 CDMO에 의존하고 있습니다. 또한, 기술 발전과 엔드투엔드 경구용 고형제 개발 및 제조 서비스에서 CDMO에 대한 의존도 증가도 시장을 견인할 것으로 예측됩니다.

만성질환과 감염성 질환 증가는 새로운 치료법에 대한 수요를 견인하는 중요한 요인입니다. 또한, 고령화 인구 증가는 만성질환 발병률 상승에 기여하고 있으며, 이는 새로운 치료법에 대한 수요를 더욱 촉진하고 있습니다. 기존 약물에 대한 부작용도 시장 성장에 기여하는 요인으로, 새로운 치료 옵션에 대한 수요를 증가시키고 있습니다.

또한, 약물 전달 기술의 지속적인 발전, OSD 개발 확대를 위한 위탁개발생산기관(CDMO)의 투자 증가, 신규 치료법에 대한 수요 증가로 인해 현재 시장에는 다양한 고형제 제제가 유통되고 있으며, 이 모든 것이 시장 성장을 더욱 촉진하고 있습니다.

제품별 시장 점유율(2024년 및 2033년)
경구 고형 제제 CDMO 시장 : 제품별 변동 분석
세계의 경구 고형 제제 CDMO 시장 규모와 동향 분석(제품별, 2021-2033년)
정제
- 압축 정제
- 구강 붕해정(ODT)
- 씹어먹는 정제
- 2층 또는 3층 정제
- 설하 정제 또는 구강 점막용 정제
- 기타
캡슐
- 하드 젤라틴 캡슐
- 소프트 젤라틴 캡슐
분말
과립
기타

제5장 경구 고형 제제 CDMO 시장 : 메커니즘별 추정 및 동향 분석

메커니즘별 시장 점유율(2024년 및 2033년)
세계의 경구 고형 제제 CDMO 시장 : 메커니즘별 변동 분석
세계 경구 고형 제제 CDMO 시장 규모와 동향 분석(메커니즘별, 2021-2033년)
즉시 방출
지연 방출
제어 방출

제6장 경구 고형 제제 CDMO 시장 : 약효별 추정 및 동향 분석

약효별 시장 점유율(2024년 및 2033년)
경구 고형 제제 CDMO 시장 : 약효별 변동 분석
세계의 경구 고형 제제 CDMO 시장 규모와 동향 분석(약효별, 2021-2033년)
고효력 의약품
중효력 의약품
저효력 의약품

제7장 경구 고형 제제 CDMO 시장 : 서비스별 추정 및 동향 분석

서비스별 시장 점유율(2024년 및 2033년)
경구 고형 제제 CDMO 시장 : 서비스별 변동 분석
세계의 경구 고형 제제 CDMO 시장 규모와 동향 분석(서비스별, 2021-2033년)
수탁 개발
제조 수탁
포장 및 라벨
규제 관련 업무
물류 및 보관
기타

제8장 경구 고형 제제 CDMO 시장 : 최종 용도별 추정 및 동향 분석

최종 용도별 시장 점유율(2024년 및 2033년)
경구 고형 제제 CDMO 시장 : 최종 용도별 변동 분석
세계의 경구 고형 제제 CDMO 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
대기업
중규모/소규모 기업
기타

제9장 경구 고형 제제 CDMO 시장 : 지역별 추정 및 동향 분석

지역별 시장 대시보드
경구 고형 제제 CDMO 시장 : 지역별 변동 분석
시장 규모와 예측, 동향 분석(2021-2033년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트
- 카타르
- 오만

제10장 경쟁 구도

참가 기업 개요
기업 시장 현황 분석
기업 분류
전략 매핑
기업 개요/리스트
- Lonza
- Thermo Fisher Scientific Inc.
- Cambrex Corporation
- Catalent, Inc.
- Siegrfried Holding AG
- Recipharm AB
- CordenPharma International
- Boehringer Ingelheim
- Piramal Pharma Solutions
- Aenova Group
- Almac Group
- Jubilant Pharmova Limited
- Delpharm
- AbbVie Contract Manufacturing
- Next Pharma AB
- Rubicon Research Pvt. Ltd.
- Quotient Sciences
- SPI Pharma
- DPT Laboratories Ltd.
- Alcami Corporation

LSH

영문 목차

영문목차

Oral Solid Dosage CDMO Market Summary

The global oral solid dosage CDMO market size was estimated at USD 43.65 billion in 2024 and is projected to reach USD 77.06 billion by 2033, growing at a CAGR of 6.56% from 2025 to 2033. The market growth is driven by a rising demand for cost-efficient drug development, increasing outsourcing by pharmaceutical and biotech companies, and growing consumption of tablets and capsules for chronic and lifestyle diseases, owing to ease of administration and precise dosage, which enhances the requirement for oral solid dosage CDMO services.

Other factors contributing to market growth include the expansion of generic drugs, patent expiries, and the need for flexible manufacturing capacity. Most companies rely on CDMOs to access advanced formulation capabilities, scale up production efficiently, and meet stringent regulatory and quality requirements. In addition, technological advancement and increased reliance on CDMOs for end-to-end OSD development and manufacturing services are expected to drive the market.

The growing prevalence of chronic and infectious diseases is a significant factor driving the demand for novel therapies. In addition, the growing geriatric population is contributing to the rising incidence of chronic diseases, further supporting the demand for novel therapies. Another factor contributing to market growth is adverse drug reactions to existing drugs, which have increased the demand for novel treatment options.

Moreover, several solid dosage forms are currently available on the market due to ongoing advancements in drug delivery technology, rising investments by contract development and manufacturing organizations (CDMOs) to expand OSD development, and increasing demand for novel therapies, all of which further contribute to market growth.

Global Oral Solid Dosage Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oral solid dosage CDMO market report based on product, mechanism, drug potency, service, end use, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Tablets
- Compressed Tablets
- Orally Disintegrating Tablets (ODT)
- Chewable Tablets
- Bi-layer or Tri-layer Tablets
- Sublingual or Buccal Tablets
- Others
Capsules
- Hard Gelatin Capsules
- Soft Gelatin Capsules
Powders
Granules
Others
Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
Immediate Release
Delayed Release
Controlled Release
Drug Potency Outlook (Revenue, USD Million, 2021 - 2033)
High Potent Drugs
Moderate Potent Drugs
Low Potent Drugs
Service Outlook (Revenue, USD Million, 2021 - 2033)
Contract Development
Contract Manufacturing
Packaging and Labelling
Regulatory Affairs
Logistics & Storage
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Large Size Companies
Medium & Small Size Companies
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Norway
- Denmark
Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Mechanism
- 1.2.3. Drug Potency
- 1.2.4. Service
- 1.2.5. End Use
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Top-Down Analysis
- 1.7.3. Botton-Up Approach
- 1.7.4. Multivariate Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Oral Solid Dosage CDMO Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Value Chain Analysis
- 3.6.1. Supply Trends
- 3.6.2. Demand Trends
3.7. Market Analysis Tools
- 3.7.1. Porter's Five Force Analysis
- 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Oral Solid Dosage CDMO Market: Product Estimates & Trend Analysis

4.1. Product Market Share, 2024 & 2033
4.2. Product Segment Dashboard
4.3. Oral Solid Dosage CDMO Market: Product Movement Analysis
4.4. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.5. Tablets
- 4.5.1. Tablets Market Estimates & Forecasts, 2021 to 2033 (USD Million)
- 4.5.2. Compressed Tablets
  - 4.5.2.1. Compressed Tablets Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 4.5.3. Orally Disintegrating Tablets (ODT)
  - 4.5.3.1. Orally Disintegrating Tablets (ODT) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 4.5.4. Chewable Tablets
  - 4.5.4.1. Chewable Tablets Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 4.5.5. Bi-layer or Tri-layer Tablets
  - 4.5.5.1. Bi-layer or Tri-layer Tablets Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 4.5.6. Sublingual or Buccal Tablets
  - 4.5.6.1. Sublingual or Buccal Tablets Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 4.5.7. Others
  - 4.5.7.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)
4.6. Capsules
- 4.6.1. Capsules Market Estimates & Forecasts, 2021 to 2033 (USD Million)
- 4.6.2. Hard Gelatin Capsules
  - 4.6.2.1. Hard Gelatin Capsules Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 4.6.3. Soft Gelatin Capsules
  - 4.6.3.1. Soft Gelatin Capsules Market Estimates & Forecasts, 2021 - 2033 (USD Million)
4.7. Powder
- 4.7.1. Powder Market Estimates & Forecasts, 2021 - 2033 (USD Million)
4.8. Granules
- 4.8.1. Granules Market Estimates & Forecasts, 2021 - 2033 (USD Million)
4.9. Others
- 4.9.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oral Solid Dosage CDMO Market: Mechanism Estimates & Trend Analysis

5.1. Mechanism Market Share, 2024 & 2033
5.2. Mechanism Segment Dashboard
5.3. Global Oral Solid Dosage CDMO Market: Mechanism Movement Analysis
5.4. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Mechanism, 2021 to 2033 (USD Million)
5.5. Immediate Release
- 5.5.1. Immediate Release Market Estimates & Forecasts, 2021 - 2033 (USD Million)
5.6. Delayed Release
- 5.6.1. Delayed Release Market Estimates & Forecasts, 2021 - 2033 (USD Million)
5.7. Controlled Release
- 5.7.1. Controlled Release Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oral Solid Dosage CDMO Market: Drug Potency Estimates & Trend Analysis

6.1. Drug Potency Market Share, 2024 & 2033
6.2. Drug Potency Segment Dashboard
6.3. Oral Solid Dosage CDMO Market: Drug Potency Movement Analysis
6.4. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Drug Potency, 2021 to 2033 (USD Million)
6.5. High Potent Drugs
- 6.5.1. High Potent Drugs Market Estimates & Forecasts, 2021 - 2033 (USD Million)
6.6. Moderate Potent Drugs
- 6.6.1. Moderate Potent Drugs Market Estimates & Forecasts, 2021 - 2033 (USD Million)
6.7. Low Potent Drugs
- 6.7.1. Low Potent Drugs Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oral Solid Dosage CDMO Market: Service Estimates & Trend Analysis

7.1. Service Market Share, 2024 & 2033
7.2. Service Segment Dashboard
7.3. Oral Solid Dosage CDMO Market: Service Movement Analysis
7.4. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
7.5. Contract Development
- 7.5.1. Contract Development Market Estimates & Forecasts, 2021 - 2033 (USD Million)
7.6. Contract Manufacturing
- 7.6.1. Contract Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Million)
7.7. Packaging and Labelling
- 7.7.1. Packaging and Labelling Market Estimates & Forecasts, 2021 - 2033 (USD Million)
7.8. Regulatory Affairs
- 7.8.1. Regulatory Affairs Market Estimates & Forecasts, 2021 - 2033 (USD Million)
7.9. Logistics & Storage
- 7.9.1. Logistics & Storage Market Estimates & Forecasts, 2021 - 2033 (USD Million)
7.10. Others
- 7.10.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Oral Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

8.1. End Use Market Share, 2024 & 2033
8.2. End Use Segment Dashboard
8.3. Oral Solid Dosage CDMO Market: End Use Movement Analysis
8.4. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
8.5. Large Size Companies
- 8.5.1. Large Size Companies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
8.6. Medium & Small Size Companies
- 8.6.1. Medium & Small Size Companies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
8.7. Others
- 8.7.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Oral Solid Dosage CDMO Market: Regional Estimates & Trend Analysis

9.1. Regional Market Dashboard
9.2. Oral Solid Dosage CDMO Market: Regional Movement Analysis
9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
9.4. North America
- 9.4.1. North America Oral Solid Dosage CDMO Market Estimates & Forecasts, By Country, 2021 - 2033 (USD Million)
- 9.4.2. U.S.
  - 9.4.2.1. Key Country Dynamics
  - 9.4.2.2. Regulatory Framework
  - 9.4.2.3. U.S. Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.4.3. Canada
  - 9.4.3.1. Key Country Dynamics
  - 9.4.3.2. Regulatory Framework
  - 9.4.3.3. U.S. Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.4.4. Mexico
  - 9.4.4.1. Key Country Dynamics
  - 9.4.4.2. Regulatory Framework
  - 9.4.4.3. Mexico Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
9.5. Europe
- 9.5.1. Europe Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.5.2. UK
  - 9.5.2.1. Key Country Dynamics
  - 9.5.2.2. Regulatory Framework
  - 9.5.2.3. UK Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.5.3. Germany
  - 9.5.3.1. Key Country Dynamics
  - 9.5.3.2. Regulatory Framework
  - 9.5.3.3. Germany Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.5.4. France
  - 9.5.4.1. Key Country Dynamics
  - 9.5.4.2. Regulatory Framework
  - 9.5.4.3. France Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.5.5. Italy
  - 9.5.5.1. Key Country Dynamics
  - 9.5.5.2. Regulatory Framework
  - 9.5.5.3. Italy Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.5.6. Spain
  - 9.5.6.1. Key Country Dynamics
  - 9.5.6.2. Regulatory Framework
  - 9.5.6.3. Spain Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.5.7. Denmark
  - 9.5.7.1. Key Country Dynamics
  - 9.5.7.2. Regulatory Framework
  - 9.5.7.3. Denmark Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.5.8. Sweden
  - 9.5.8.1. Key Country Dynamics
  - 9.5.8.2. Regulatory Framework
  - 9.5.8.3. Sweden Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.5.9. Norway
  - 9.5.9.1. Key Country Dynamics
  - 9.5.9.2. Regulatory Framework
  - 9.5.9.3. Norway Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
9.6. Asia Pacific
- 9.6.1. Asia Pacific Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.6.2. Japan
  - 9.6.2.1. Key Country Dynamics
  - 9.6.2.2. Regulatory Framework
  - 9.6.2.3. Japan Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.6.3. China
  - 9.6.3.1. Key Country Dynamics
  - 9.6.3.2. Regulatory Framework
  - 9.6.3.3. China Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.6.4. India
  - 9.6.4.1. Key Country Dynamics
  - 9.6.4.2. Regulatory Framework
  - 9.6.4.3. India Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.6.5. Australia
  - 9.6.5.1. Key Country Dynamics
  - 9.6.5.2. Regulatory Framework
  - 9.6.5.3. Australia Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.6.6. South Korea
  - 9.6.6.1. Key Country Dynamics
  - 9.6.6.2. Regulatory Framework
  - 9.6.6.3. South Korea Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.6.7. Thailand
  - 9.6.7.1. Key Country Dynamics
  - 9.6.7.2. Regulatory Framework
  - 9.6.7.3. Thailand Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
9.7. Latin America
- 9.7.1. Latin America Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.7.2. Brazil
  - 9.7.2.1. Key Country Dynamics
  - 9.7.2.2. Regulatory Framework
  - 9.7.2.3. Japan Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.7.3. Argentina
  - 9.7.3.1. Key Country Dynamics
  - 9.7.3.2. Regulatory Framework
  - 9.7.3.3. China Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
9.8. Middle East and Africa
- 9.8.1. Middle East and Africa Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.8.2. South Africa
  - 9.8.2.1. Key Country Dynamics
  - 9.8.2.2. Regulatory Framework
  - 9.8.2.3. South Africa Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.8.3. Saudi Arabia
  - 9.8.3.1. Key Country Dynamics
  - 9.8.3.2. Regulatory Framework
  - 9.8.3.3. Saudi Arabia Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.8.4. UAE
  - 9.8.4.1. Key Country Dynamics
  - 9.8.4.2. Regulatory Framework
  - 9.8.4.3. UAE Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.8.5. Kuwait
  - 9.8.5.1. Key Country Dynamics
  - 9.8.5.2. Regulatory Framework
  - 9.8.5.3. Kuwait Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.8.6. Qatar
  - 9.8.6.1. Key Country Dynamics
  - 9.8.6.2. Regulatory Framework
  - 9.8.6.3. Qatar Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 9.8.7. Oman
  - 9.8.7.1. Key Country Dynamics
  - 9.8.7.2. Regulatory Framework
  - 9.8.7.3. Oman Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

10.1. Participant Overview
10.2. Company Market Position Analysis
10.3. Company Categorization
10.4. Strategy Mapping
10.5. Company Profiles/Listing
- 10.5.1. Lonza
  - 10.5.1.1. Company Overview
  - 10.5.1.2. Financial Performance
  - 10.5.1.3. Product Benchmarking
  - 10.5.1.4. Strategic Initiatives
- 10.5.2. Thermo Fisher Scientific Inc.
  - 10.5.2.1. Company Overview
  - 10.5.2.2. Financial Performance
  - 10.5.2.3. Product Benchmarking
  - 10.5.2.4. Strategic Initiatives
- 10.5.3. Cambrex Corporation
  - 10.5.3.1. Company Overview
  - 10.5.3.2. Financial Performance
  - 10.5.3.3. Product Benchmarking
  - 10.5.3.4. Strategic Initiatives
- 10.5.4. Catalent, Inc.
  - 10.5.4.1. Company Overview
  - 10.5.4.2. Financial Performance
  - 10.5.4.3. Product Benchmarking
  - 10.5.4.4. Strategic Initiatives
- 10.5.5. Siegrfried Holding AG
  - 10.5.5.1. Company Overview
  - 10.5.5.2. Financial Performance
  - 10.5.5.3. Product Benchmarking
  - 10.5.5.4. Strategic Initiatives
- 10.5.6. Recipharm AB
  - 10.5.6.1. Company Overview
  - 10.5.6.2. Financial Performance
  - 10.5.6.3. Product Benchmarking
  - 10.5.6.4. Strategic Initiatives
- 10.5.7. CordenPharma International
  - 10.5.7.1. Company Overview
  - 10.5.7.2. Financial Performance
  - 10.5.7.3. Product Benchmarking
  - 10.5.7.4. Strategic Initiatives
- 10.5.8. Boehringer Ingelheim
  - 10.5.8.1. Company Overview
  - 10.5.8.2. Financial Performance
  - 10.5.8.3. Product Benchmarking
  - 10.5.8.4. Strategic Initiatives
- 10.5.9. Piramal Pharma Solutions
  - 10.5.9.1. Company Overview
  - 10.5.9.2. Financial Performance
  - 10.5.9.3. Product Benchmarking
  - 10.5.9.4. Strategic Initiatives
- 10.5.10. Aenova Group
  - 10.5.10.1. Company Overview
  - 10.5.10.2. Financial Performance
  - 10.5.10.3. Product Benchmarking
  - 10.5.10.4. Strategic Initiatives
- 10.5.11. Almac Group
  - 10.5.11.1. Company Overview
  - 10.5.11.2. Financial Performance
  - 10.5.11.3. Product Benchmarking
  - 10.5.11.4. Strategic Initiatives
- 10.5.12. Jubilant Pharmova Limited
  - 10.5.12.1. Company Overview
  - 10.5.12.2. Financial Performance
  - 10.5.12.3. Product Benchmarking
  - 10.5.12.4. Strategic Initiatives
- 10.5.13. Delpharm
  - 10.5.13.1. Company Overview
  - 10.5.13.2. Financial Performance
  - 10.5.13.3. Product Benchmarking
  - 10.5.13.4. Strategic Initiatives
- 10.5.14. AbbVie Contract Manufacturing
  - 10.5.14.1. Company Overview
  - 10.5.14.2. Financial Performance
  - 10.5.14.3. Product Benchmarking
  - 10.5.14.4. Strategic Initiatives
- 10.5.15. Next Pharma AB
  - 10.5.15.1. Company Overview
  - 10.5.15.2. Financial Performance
  - 10.5.15.3. Product Benchmarking
  - 10.5.15.4. Strategic Initiatives
- 10.5.16. Rubicon Research Pvt. Ltd.
  - 10.5.16.1. Company Overview
  - 10.5.16.2. Financial Performance
  - 10.5.16.3. Product Benchmarking
  - 10.5.16.4. Strategic Initiatives
- 10.5.17. Quotient Sciences
  - 10.5.17.1. Company Overview
  - 10.5.17.2. Financial Performance
  - 10.5.17.3. Product Benchmarking
  - 10.5.17.4. Strategic Initiatives
- 10.5.18. SPI Pharma
  - 10.5.18.1. Company Overview
  - 10.5.18.2. Financial Performance
  - 10.5.18.3. Product Benchmarking
  - 10.5.18.4. Strategic Initiatives
- 10.5.19. DPT Laboratories Ltd.
  - 10.5.19.1. Company Overview
  - 10.5.19.2. Financial Performance
  - 10.5.19.3. Product Benchmarking
  - 10.5.19.4. Strategic Initiatives
- 10.5.20. Alcami Corporation
  - 10.5.20.1. Company Overview
  - 10.5.20.2. Financial Performance
  - 10.5.20.3. Product Benchmarking
  - 10.5.20.4. Strategic Initiatives